Emergence Therapeutics
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody-drug conjugates (ADC) to treat high-need cancers. Its lead program combines a highly specific antibody with optimized linker and payload technology to target Nectin-4 – an important target for a broad range of cancers which has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers by the US Food and Drug Administration. Emergence is also actively exploring opportunities to develop further first- or best-in-class ADCs driven by therapeutic need.
Tech Stack (9 technologies)
Frequently Asked Questions
What technologies does Emergence Therapeutics use?+
Emergence Therapeutics uses 9 technologies including Adobe Client Data Layer, Adobe Experience Manager Franklin, Adobe Experience Platform Launch.
What industry is Emergence Therapeutics in?+
Emergence Therapeutics operates in the Biotechnology industry.
Where is Emergence Therapeutics based?+
Emergence Therapeutics is headquartered in Germany.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026